Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A billion nonredundant molecular interactions lie buried in the biomedical literature. A text-mining approach could help scientists better exploit this knowledge.
An important molecule for growth recently received approval in the US. This approval heralds the first medical application of insulin-like growth factor 1 (IGF-1) as a drug to promote growth in a rare group of very small children.
Chiron's ongoing problems in influenza vaccine production have raised serious questions about the company's future ability to compete in this particular segment of the vaccine market.
Cash-starved biotech companies in Korea are hoping to capitalize on changes to the listing rules for the Korean stock market introduced earlier this year to go public
Under the gun of increased oversight on drug company advertising by the US Food and Drug Administration, the Washington, DC-based industry group Pharmaceutical Research and Manufacturers Association (PhRMA) on 29 July announced a set of guiding principles for ethical practices in direct to consumer advertising (DTC).
A hands-off philosophy based on investing in people has served Jean Deleage well over almost 35 years of venture capital investing in the life sciences. He reflects on biotech investment trends.
Deep-sea prospecting is unveiling bizarre species of microbes that already are providing new sources of industrial enzymes, and could be a source of novel therapeutics. Will the lack of treaties governing activities in international waters compromise the commercial potential of the ocean's largesse? Cormac Sheridan investigates.
Academic ownership of intellectual property facilitated wide dissemination and commercialization of antibody technology. Moves at the University of Cambridge to reclaim institutional IP rights should thus be treated with caution.
India's thriving biotechnology industry is threatened by a change in the law. Will the current high levels of investment be enough to secure its future?
